
Anesthetic Effect Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Anesthetic Effect Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect - Drugs In Development, 2022, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape.
Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of adverse reactions to anesthesia and drug allergies.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anesthetic Effect - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Anesthetic Effect (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anesthetic Effect (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 4, 6, 3, 4, 2, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Anesthetic Effect (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect - Drugs In Development, 2022, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape.
Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of adverse reactions to anesthesia and drug allergies.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anesthetic Effect - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Anesthetic Effect (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anesthetic Effect (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 4, 6, 3, 4, 2, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Anesthetic Effect (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Anesthetic Effect (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Anesthetic Effect (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anesthetic Effect (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anesthetic Effect (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anesthetic Effect (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anesthetic Effect (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anesthetic Effect (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
97 Pages
- Introduction
- Global Markets Direct Report Coverage
- Anesthetic Effect – Overview
- Anesthetic Effect – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Anesthetic Effect – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Anesthetic Effect – Companies Involved in Therapeutics Development
- American Genomics LLC
- Andros Pharmaceuticals Co Ltd
- Avecho Biotechnology Ltd
- Baudax Bio Inc
- Biotts SA
- Chengdu List Pharmaceutical Co Ltd
- Crescita Therapeutics Inc
- Cuda Pharmaceuticals LLC
- Dongkook Pharmaceutical Co Ltd
- Expanesthetics Inc
- Hangzhou Adamerck Pharmlabs Inc
- Hefei Cosource Pharmaceutical Inc
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Nhwa Pharmaceutical Co Ltd
- Lannett Co Inc
- LipoSeuticals Inc
- MedinCell SA
- Nevakar Injectables Inc
- NutriBand Inc
- PAION AG
- Protheragen Inc
- Sichuan Haisco Pharmaceutical Co Ltd
- Sintetica SA
- Sphaera Pharma Pte Ltd
- Yichang Humanwell Pharmaceutical Co Ltd
- Anesthetic Effect – Drug Profiles
- (lidocaine + tetracaine) – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AMP-100 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Aom-0498 – Drug Profile
- Product Description
- Mechanism Of Action
- Aom-0765 – Drug Profile
- Product Description
- Mechanism Of Action
- APC-310 – Drug Profile
- Product Description
- Mechanism Of Action
- articaine hydrochloride – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BX-1000 – Drug Profile
- Product Description
- Mechanism Of Action
- BX-2000 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ciprofol – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- cocaine hydrochloride – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- cysteine – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DKM-413 – Drug Profile
- Product Description
- Mechanism Of Action
- EL-052 – Drug Profile
- Product Description
- Mechanism Of Action
- esketamine hydrochloride – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- etomidate hydrochloride – Drug Profile
- Product Description
- Mechanism Of Action
- EXPS-01 – Drug Profile
- Product Description
- Mechanism Of Action
- EXPS-05 – Drug Profile
- Product Description
- Mechanism Of Action
- EXPS-09 – Drug Profile
- Product Description
- Mechanism Of Action
- fospropofol disodium – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- HYRPB-21 – Drug Profile
- Product Description
- Mechanism Of Action
- isoflurane – Drug Profile
- Product Description
- Mechanism Of Action
- lidocaine – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LK-396 – Drug Profile
- Product Description
- Mechanism Of Action
- morphine glucuronide – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MTCA-4 – Drug Profile
- Product Description
- Mechanism Of Action
- NH-600001 – Drug Profile
- Product Description
- Mechanism Of Action
- NVK-003 – Drug Profile
- Product Description
- Mechanism Of Action
- propofol – Drug Profile
- Product Description
- Mechanism Of Action
- remimazolam – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- remimazolam besylate – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ropivacaine – Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit NMDA Receptor for Anaesthesia – Drug Profile
- Product Description
- Mechanism Of Action
- SPR-819 – Drug Profile
- Product Description
- Mechanism Of Action
- Anesthetic Effect – Dormant Projects
- Anesthetic Effect – Discontinued Products
- Anesthetic Effect – Product Development Milestones
- Featured News & Press Releases
- Feb 25, 2022: Haisco announces approval of the new indication marketing application for Cyclopofol Injection
- Feb 22, 2022: Harrow Health announces FDA acceptance of New Drug Application for AMP-100
- Feb 03, 2021: Liaoning Haisco Pharmaceutical : Innovative drug cyclopofol injection obtained Drug Registration Certificate for induction of general anesthesia
- Jan 18, 2021: Innovative drug HSK3486 emulsion injection US Phase III clinical trial application approved by FDA
- Nov 08, 2020: Paion announces progress with remimazolam by its partner Yichang Humanwell in China
- Jul 08, 2020: PAION announces successful product launch of Anerem (remimazolam) in Japan by Mundipharma
- Jun 10, 2020: Paion reports progress with Byfavo (Remimazolam) by its licensee Acacia in the U.s.
- Jun 02, 2020: PAION announces approval of compassionate use for remimazolam in ITALIAN HOSPITAL
- Apr 02, 2020: Paion closes Enrollment in EU phase III trial with remimazolam in general anesthesia
- Mar 12, 2020: Acacia Pharma announces brief extension of FDA review period for NDA for BYFAVO
- Mar 08, 2020: PAION announces approval of compassionate use progarm for remimazolam in Belgium
- Jan 23, 2020: PAION : Mundipharma receives market approval for Anerem (Remimazolam) in general anesthesia in Japan
- Jan 13, 2020: Lannett announces FDA approval of NDA for branded anesthetic product, Cocaine Hydrochloride nasal solution 4%
- Dec 30, 2019: Paion announces submission of new drug application for remimazolam by its licensee Hana Pharm in South Korea
- Nov 20, 2019: Paion announces submission of the marketing authorization application for Remimazolam in procedural sedation to the European Medicines Agency
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Anesthetic Effect, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Universities/Institutes, 2022
- Table 4: Products under Development by Companies, 2022
- Table 5: Products under Development by Companies, 2022 (Contd..1)
- Table 6: Products under Development by Universities/Institutes, 2022
- Table 7: Number of Products by Stage and Target, 2022
- Table 8: Number of Products by Stage and Mechanism of Action, 2022
- Table 9: Number of Products by Stage and Route of Administration, 2022
- Table 10: Number of Products by Stage and Molecule Type, 2022
- Table 11: Anesthetic Effect – Pipeline by American Genomics LLC, 2022
- Table 12: Anesthetic Effect – Pipeline by Andros Pharmaceuticals Co Ltd, 2022
- Table 13: Anesthetic Effect – Pipeline by Avecho Biotechnology Ltd, 2022
- Table 14: Anesthetic Effect – Pipeline by Baudax Bio Inc, 2022
- Table 15: Anesthetic Effect – Pipeline by Biotts SA, 2022
- Table 16: Anesthetic Effect – Pipeline by Chengdu List Pharmaceutical Co Ltd, 2022
- Table 17: Anesthetic Effect – Pipeline by Crescita Therapeutics Inc, 2022
- Table 18: Anesthetic Effect – Pipeline by Cuda Pharmaceuticals LLC, 2022
- Table 19: Anesthetic Effect – Pipeline by Dongkook Pharmaceutical Co Ltd, 2022
- Table 20: Anesthetic Effect – Pipeline by Expanesthetics Inc, 2022
- Table 21: Anesthetic Effect – Pipeline by Hangzhou Adamerck Pharmlabs Inc, 2022
- Table 22: Anesthetic Effect – Pipeline by Hefei Cosource Pharmaceutical Inc, 2022
- Table 23: Anesthetic Effect – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Table 24: Anesthetic Effect – Pipeline by Jiangsu Nhwa Pharmaceutical Co Ltd, 2022
- Table 25: Anesthetic Effect – Pipeline by Lannett Co Inc, 2022
- Table 26: Anesthetic Effect – Pipeline by LipoSeuticals Inc, 2022
- Table 27: Anesthetic Effect – Pipeline by MedinCell SA, 2022
- Table 28: Anesthetic Effect – Pipeline by Nevakar Injectables Inc, 2022
- Table 29: Anesthetic Effect – Pipeline by NutriBand Inc, 2022
- Table 30: Anesthetic Effect – Pipeline by PAION AG, 2022
- Table 31: Anesthetic Effect – Pipeline by Protheragen Inc, 2022
- Table 32: Anesthetic Effect – Pipeline by Sichuan Haisco Pharmaceutical Co Ltd, 2022
- Table 33: Anesthetic Effect – Pipeline by Sintetica SA, 2022
- Table 34: Anesthetic Effect – Pipeline by Sphaera Pharma Pte Ltd, 2022
- Table 35: Anesthetic Effect – Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, 2022
- Table 36: Anesthetic Effect – Dormant Projects, 2022
- Table 37: Anesthetic Effect – Dormant Projects, 2022 (Contd..1)
- Table 38: Anesthetic Effect – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Anesthetic Effect, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products by Top 10 Targets, 2022
- Figure 4: Number of Products by Stage and Top 10 Targets, 2022
- Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Routes of Administration, 2022
- Figure 8: Number of Products by Stage and Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.